title: Regional responsiveness of the tibia to intermittent administration of parathyroid hormone as affected by skeletal unloading.
abstract: To determine whether the acute inhibition of bone formation and deficit in bone mineral induced by skeletal unloading can be prevented, we studied the effects of intermittent parathyroid hormone (PTH) administration (8 micrograms/100 g/day) on growing rats submitted to 8 days of skeletal unloading. Loss of weight bearing decreased periosteal bone formation by 34 and 51% at the tibiofibular junction and tibial midshaft, respectively, and reduced the normal gain in tibial mass by 35%. Treatment with PTH of normally loaded and unloaded animals increased mRNA for osteocalcin (+58 and +148%, respectively), cancellous bone volume in the proximal tibia (+41 and +42%, respectively), and bone formation at the tibiofibular junction (+27 and +27%, respectively). Formation was also stimulated at the midshaft in unloaded (+47%, p < 0.05), but not loaded animals (-3%, NS). Although cancellous bone volume was preserved in PTH-treated, unloaded animals, PTH did not restore periosteal bone formation to normal nor prevent the deficit in overall tibial mass induced by unloading. We conclude that the effects of PTH on bone formation are region specific and load dependent. PTH can prevent the decrease in cancellous bone volume and reduce the decrement in cortical bone formation induced by loss of weight bearing.
authors.affiliation: Department of Medicine, University of California, San Francisco, USA.
authors.forename: B P
authors.initials: BP
authors.lastname: Halloran
authors.forename: D D
authors.initials: DD
authors.lastname: Bikle
authors.forename: J
authors.initials: J
authors.lastname: Harris
authors.forename: S
authors.initials: S
authors.lastname: Tanner
authors.forename: T
authors.initials: T
authors.lastname: Curren
authors.forename: E
authors.initials: E
authors.lastname: Morey-Holton
mesh_terms: D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control*; D008297:Male; D015675:Osteocalcin / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000187:drug effects* / Q000502:physiology*; D018474:Weightlessness Simulation / Q000009:adverse effects*
chemical_list: D010281:Parathyroid Hormone; D012333:RNA, Messenger; D015675:Osteocalcin